Valeant sets March 15 release for delayed Q4 results

Valeant ($VRX) investors eager for answers will get some on March 15, the company promised. That's when it now intends to release preliminary quarterly results--which it delayed last week for a variety of reasons, including pneumonia-stricken CEO J. Michael Pearson's comeback--and it'll hold a conference call that day, too. Release | More

Suggested Articles

Johnson & Johnson faces a litany of problems, but executives are clearly not concerned—at least not about the company's short-term fortunes.

This week, Goldman Sachs resurrected a burning question: How can pharma companies profit from curing patients with one-time gene and cell therapies?

CMS has determined how it'll pay for Gilead's CAR-T cancer therapy, Yescarta, for outpatient use, but hasn't yet decided on Gilead's…